Literature DB >> 21536729

Sweet DREAMs for Hippo.

Frederick A Dick1, Joe S Mymryk.   

Abstract

The Hippo pathway coordinates organ size and cell proliferation. The retinoblastoma family of proteins regulates progression through the G0/G1 phase of the cell cycle. Disruption of either pathway contributes to cancer formation. Three recent studies in Genes & Development reveal how cellular proliferation is coordinated between these pathways. Here we discuss the implications of these studies and the new questions that they raise.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536729      PMCID: PMC3084021          DOI: 10.1101/gad.2050411

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  25 in total

1.  Extra-embryonic function of Rb is essential for embryonic development and viability.

Authors:  Lizhao Wu; Alain de Bruin; Harold I Saavedra; Maja Starovic; Anthony Trimboli; Ying Yang; Jana Opavska; Pamela Wilson; John C Thompson; Michael C Ostrowski; Thomas J Rosol; Laura A Woollett; Michael Weinstein; James C Cross; Michael L Robinson; Gustavo Leone
Journal:  Nature       Date:  2003-02-27       Impact factor: 49.962

2.  Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes.

Authors:  Michael Korenjak; Barbie Taylor-Harding; Ulrich K Binné; John S Satterlee; Olivier Stevaux; Rein Aasland; Helen White-Cooper; Nick Dyson; Alexander Brehm
Journal:  Cell       Date:  2004-10-15       Impact factor: 41.582

3.  A kinase shRNA screen links LATS2 and the pRB tumor suppressor.

Authors:  Katrin Tschöp; Andrew R Conery; Larisa Litovchick; James A Decaprio; Jeffrey Settleman; Ed Harlow; Nicholas Dyson
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

Review 4.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

5.  pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes.

Authors:  R K Hurford; D Cobrinik; M H Lee; N Dyson
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

Review 6.  The retinoblastoma tumour suppressor in development and cancer.

Authors:  Marie Classon; Ed Harlow
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

7.  DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly.

Authors:  Larisa Litovchick; Laurence A Florens; Selene K Swanson; Michael P Washburn; James A DeCaprio
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

Review 8.  The RB and p53 pathways in cancer.

Authors:  Charles J Sherr; Frank McCormick
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

Review 9.  New molecular tools for efficient screening of cervical cancer.

Authors:  M von Knebel Doeberitz
Journal:  Dis Markers       Date:  2001       Impact factor: 3.434

10.  Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences.

Authors:  B O Williams; E M Schmitt; L Remington; R T Bronson; D M Albert; R A Weinberg; T Jacks
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

View more
  4 in total

Review 1.  Mechanosensitive mechanisms in transcriptional regulation.

Authors:  Akiko Mammoto; Tadanori Mammoto; Donald E Ingber
Journal:  J Cell Sci       Date:  2012-07-13       Impact factor: 5.285

Review 2.  Conserved RB functions in development and tumor suppression.

Authors:  Gabriel M Gordon; Wei Du
Journal:  Protein Cell       Date:  2011-12-17       Impact factor: 14.870

3.  The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.

Authors:  N Reuven; J Adler; V Meltser; Y Shaul
Journal:  Cell Death Differ       Date:  2013-07-12       Impact factor: 15.828

4.  The role of the hippo pathway in melanocytes and melanoma.

Authors:  Ji Eun Kim; Graeme J Finlay; Bruce C Baguley
Journal:  Front Oncol       Date:  2013-05-16       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.